Parkinson's Disease/Movement Disorders News

Improvements in “on” time were observed as early as day 3 after treatment initiation with an investigational subcutaneous combination therapy for Parkinson’s disease, which also led to significant improvement by day 7, data show.

Antidopaminergic medications were linked to worsening cognitive and functional effects that accelerate disease progression in Huntington’s disease, according to research presented at the Congress of the European Academy of Neurology.

The FDA has granted Regenerative Medicine Advanced Therapy designation to a Bay Area-based biopharmaceutical company for its autologous, fully human CD19 chimeric antigen receptor to treat those with refractory stiff person syndrome.

NYU Langone was again the top hospital in the United States for neurology and neurosurgery, according to the latest annual Best Hospitals Survey issued by U.S. News & World Report.

Merz Therapeutics announced that it has acquired assets from Acorda Therapeutics Inc. in development to treat Parkinson’s disease and multiple sclerosis.

Interim results of phase 1/2 clinical trials of an investigational gene therapy for Huntington’s disease showed that disease progression slowed by 80% at 24 months, according to the manufacturer.

A South Korean biomedical company has announced positive 1-year assessment data from a phase 1/2a clinical trial of a human embryonic stem cell-derived midbrain dopaminergic progenitor for Parkinson’s disease.

Treatment with an investigational subcutaneous combination therapy for Parkinson’s disease improved ‘good on’ time by almost 2 hours per day, was safe and efficacious with treatment effect similar across a range of subgroups.

Mission Therapeutics has been awarded $5.2 million from The Michael J. Fox Foundation for Parkinson’s Research and Parkinson’s UK to advance a selective, small molecule, brain penetrant USP30 inhibitor for Parkinson’s disease.

Makeup not only has cosmetic applications, but medical ones too.